Human Airway and Alveolar Organoids from BAL Fluid Liu, Monica Yun; Chen, Belinda; Borji, Mehdi ...
American journal of respiratory and critical care medicine,
06/2024, Letnik:
209, Številka:
12
Journal Article
We echo the latest calls that have been made to increase the capacity for antimicrobial susceptibility testing (AST) for bedaquiline for the
Mycobacterium tuberculosis
complex 1, 2. However, we would ...like to highlight the limitations of using insufficiently standardised or validated phenotypic AST methods and breakpoints as the reference standard for bedaquiline AST. Moreover, we advocate for adoption of a composite reference standard that considers genotypic AST results to minimise false-susceptible results for borderline/low-level resistance mechanisms and avoid confusion during clinical decision-making.
A composite reference standard minimises false-susceptible AST results for bedaquiline
https://bit.ly/3wAVvFm
We agree with P.J. McDowell and co-workers that the patients whose data are recorded in the UK Severe Asthma Registry (UKSAR) have, on average, more severe asthma than participants in randomised ...controlled trials (RCTs) of inhaled corticosteroid (ICS)/formoterol maintenance and reliever therapy (MART) 1, 2. However, poor generalisability from RCTs to severe asthma registries is also the case for RCTs of high dose ICS/long-acting β-agonist (LABA) plus short-acting β-agonist (SABA) reliever therapy. There are similar differences in average baseline severity between patients in the UKSAR database and participants in RCTs of high dose
versus
medium dose ICS/LABA plus SABA therapy, as with those in the MART studies (table 1) 3–13.
ICS/formoterol MART is an evidence-based alternative to high dose ICS/LABA in asthma patients at high risk of severe exacerbations; limited generalisability of RCTs to severe asthma registries applies similarly to high dose ICS/LABA therapy as to MART
https://bit.ly/4aVFrNH
